The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Thomas Yip - H.C. Wainwright & Co, LLC - Analyst
: Hi, good morning, everyone. This is Thomas Yip asking a couple of questions were asked. Thank you for taking the questions. So first question we
have just wondering, do you have any specific date or triggering events to decide on your strategic options considering that's due for as expected
that's you specified earlier early fourth quarter and that cash runway into 2025 inside you have some practically there.
Question: Thomas Yip - H.C. Wainwright & Co, LLC - Analyst
: Understood. Perhaps a while we understand that the timing details is still up in the air. So will you consider an option, whether it's indication-specific
as we understand the NDA resubmission for uncomplicated uUTI, would you consider carving out other indications possible sulopenem and also
for geographic areas as well or would certainly consider sulopenem as a single package?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 12:30PM, ITRM.OQ - Q4 2023 Iterum Therapeutics PLC Earnings Call
Question: Thomas Yip - H.C. Wainwright & Co, LLC - Analyst
: Understood. Thank you again for taking our questions, and we look forward to the NDA resubmission closing.
Question: Jason McCarthy - Maxim Group, LLC - Analyst
: Thanks, Corey. Thanks for taking the questions. Is Iterum still actively or planning to engage physicians and practices. I guess on an educational
level to talk about sulopenem ahead of any type of divestiture or partnering or the focus just getting the NDA done getting to the finish line and
seeking to divest or sell the license?
Question: Jason McCarthy - Maxim Group, LLC - Analyst
: Got it and does sulo qualify or couldn't qualify ultimately under the past our act, if it should get cleared by congress, obviously there is always
challenges in getting things done in congress these days, but it is one of the pure bipartisan bill that is out there in the Senate and that they've
heard that it's getting closer and closer. And I wonder sulo could be in that discussion for a kind of, quote-unquote, critical need antimicrobial
drug?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 12:30PM, ITRM.OQ - Q4 2023 Iterum Therapeutics PLC Earnings Call
Question: Jason McCarthy - Maxim Group, LLC - Analyst
: Got it. Thanks, Cory.
| 
